Richard G. Moore

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer

Mark S. Shahin, Domenica Lorusso, Floor J. Backes, Maria Pilar Barretina-Ginesta et autres

OBJECTIVE: To report updated patient-reported (PRO) health-related quality of life (HRQOL) findings and evaluate the effect of disease progression on HRQOL using data from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial. METHODS: Patients were randomized 2:1 to niraparib first-line maintenance or placebo. …

us, it, es, fi, fr, de, il, be, dk (code pays fourni par la source)

Psychometric evaluation of the NFOSI-18 disease related symptoms – Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004

Xiaodan Tang, Helen Huang, John D. Peipert, Anne Zola et autres

us, ph, gb (code pays fourni par la source)

Efficacy prediction for progression-free survival (PFS) and overall survival (OS) by genomic instability score (GIS) cutoffs in patients (pts) with advanced ovarian cancer (aOC): Post hoc results from the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial.

Bradley J. Monk, Ignacio Romero, David M. O’Malley, Corina Martinez Mena et autres

5565 Background: GIS is a key component of a companion diagnostic assay for determining homologous recombination deficiency (HRD) status to identify pts with aOC who may benefit from maintenance therapy. While the standard GIS cutoff to classify tumors as homologous recombination-deficient (HRd) …

us, es, be, fi, it, fr, de (code pays fourni par la source)

Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.

Ramez Nassef Eskander, Michael Sill, Lindsey Beffa, Richard G. Moore et autres

5502 Background: NRG-GY018, the only phase 3 trial examining dMMR and pMMR EC populations independently, identified a 70% and 46% reduction in the risk of disease progression or death in advanced stage or recurrent dMMR and pMMR EC patients treated with pembrolizumab …

us, ca (code pays fourni par la source)

Predictors of long-term progression-free survival in patients treated with niraparib first-line maintenance therapy in the phase 3 randomised placebo-controlled PRIMA/ENGOT-OV16/GOG-3012 trial

Antonio J. González-Martín, David M. O'Malley, Cristina Churruca Galaz, Christof Vulsteke et autres

es, us, be, se, it, fr, de (code pays fourni par la source)

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, Whitney S. Graybill et autres

OBJECTIVE: To evaluate the impact of age on the efficacy and safety of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer with a complete/partial response to first-line platinum-based chemotherapy. METHODS: Post hoc analysis of the phase 3 PRIMA/ENGOT-OV26/GOG-3012 …

it, us, es, be, ca, fi, dk, fr, de, il (code pays fourni par la source)